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Abstract  
 Drug discovery efforts are increasingly being directed at re-purposing 
old drugs for use in treatment of multidrug resistant tuberculosis (MDRTB) 
which continues to pose serious health challenges worldwide. Recent studies 
suggest that Mycobacterium smegmatis, with innate resistance to isoniazid, 
could be used as a surrogate for MDRTB screening in laboratories without 
adequate containment facilities. The current study utilized resazurin 
microtiter assay plate (REMA) to screen common household chemicals and 
non-steroidal anti-inflammatory drugs (NSAIDs) for anti-tubercular activity 
against Mycobacterium smegmatis, as a non-pathogenic surrogate of 
MDRTB. A ligand-based approach was adopted in selecting household 
chemicals; using molecular docking tools to probe for binding affinity to 
Enoyl-[acyl-carrier-protein] reductase (InhA), the main target of isoniazid. 
Among household chemicals and analgesics studied, EDTA and lauric acid 
showed the highest activity with minimum inhibitory concentration (MIC) of 
31 µg/mL and 7.8 µg/mL respectively, while Ibuprofen and aspirin exhibited 
activity with MIC of 125 µg/mL. Taken together, this study demonstrates the 
potential use of EDTA, lauric acid or NSAIDs in treatment of drug-resistant 
tuberculosis, a major contribution of the current study
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Introduction 
 Tuberculosis (TB) is a curable disease that continues to pose major 
health challenges worldwide, mainly due to increasing incidence of drug 
resistance and co-infection with HIV/AIDS. Each year, TB is responsible for 
the death of nearly 1.4 million people across the globe (The Union, 2012). 
An estimated one-third of the world population is believed to be infected 
with Mycobacterium tuberculosis (MTB), the causative agent of TB, mostly 
in the latent infestation form (WHO, 2013; O’Garra et al., 2013). As for 
people living with HIV/AIDS, TB remains the main cause of death yearly.  
According to the World Health Organization (WHO, 2013), about 13% (1.1 
million) of the 8.6 million people who developed TB in 2012 were HIV 
positive. Of the 1.3 million deaths attributable to TB in 2012, for example, 
320 000 deaths (about 20%) were from people living with HIV/AIDS, 
evidence that this co-infestation with HIV/AIDS has further complicated the 
management of the TB (WHO, 2013). 
 Drug resistance arises mostly due to inappropriate use of antibiotics 
by patients undergoing treatment for drug-susceptible active TB, though a 
person may also be directly infected by someone with multi-drug resistant 
TB (MDRTB). The combined effect of potentially severe side effects and 
required prolonged use make patient compliance to treatment regimen very 
difficult (Umesiri et al., 2010). As a result, a lot of resources – human, 
financial, and laboratory – are dedicated to adherence counseling and 
infectious control. Further complicating the control and management of 
MDRTB is the high cost associated with second-line drugs used for 
treatment of MDRTB. These factors have led to increasing incidence of 
drug-resistant strains of MTB. For instance, in 2012, 450,000 people 
developed MDRTB globally, and 170,000 deaths were reported from 
MDRTB. Although more than half of these cases were from Brazil, Russia, 
India and China (WHO, 2013; O’Garra et al., 2013); the global picture is still 
rather alarming. The challenges posed by severe side effects, huge cost and 
required prolonged use of current MDRTB drugs present a unique 
opportunity to start exploring new approaches to treating MDRTB.  
 
Repurposing Old Drugs for TB  
 An increasingly popular approach to discovering new TB drugs, 
especially new drugs against MDRTB, is to re-position and repurpose old 
drugs that are already approved for other indications. For example, linezolid 
is currently in advanced clinical trial as a treatment for MDRTB (Nzila et al., 
2011), even though it has long been used for the treatment of infections 
resistant to vancomycin, penicillin and methicillin strains. Other drugs 
currently repurposed for TB treatment (Table 1) include rifapentine 
(approved for treatment of latent TB in combination with isoniazid for 3 
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months), disulfiram, the fluroquinolones (Gatifloxacin and Moxifloxacin) 
seeking regulatory formal registration for use in TB treatment, including 
MDRTB (Nzila et al., 2011; Stop TB Alliance, 2014). Repurposing old 
drugs for treatment of TB has significant advantages, namely, existing 
knowledge of their safety, toxicity, pharmacological profiles lead to huge 
savings in time, effort and expenses (Guzman et al., 2013). 
 Repurposing old drugs for new TB treatments take either one of two 
paths: testing known antibacterial agents against other infections (spectrum 
expansion), or testing agents with no prior antibacterial profile against 
mycobacterium species (Nzila et al., 2011). 
Table 2:  Drugs being repurposed for TB or MDRTB 
 
 
 Either approach requires whole-cell phenotypic screening. Not 
surprisingly, whole-cell screening is getting renewed attention in the drug 
discovery process, compared to the more popular target-based method 
(Swinney and Anthony, 2011; Schulz et al., 2012; Visnyei et al., 2011). 
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Whole-cell phenotypic screening approach does not require clear 
understanding of underlying MMOA to be successful, and  therefore has the 
unique advantage that it is able to interrogate all biochemical targets 
simultaneously in a specific physiological environment (Swinney and 
Anthony, 2011; Schulz et al., 2012; Visnyei et al., 2011). This is even more 
important when dealing with a disease like TB that may involve different 
biological targets, and therefore presents a more efficient method to screen 
for actual biological activity against MDRTB as available data seem to 
suggest. For example, the first FDA approved antitubercular drug in over 40 
years, bedaquiline (Mahajan, 2013), and others in advanced clinical 
development (delamanid, sutezolid and SQ109) were discovered through 
phenotypic screening (Horita et al., 2012; Sotgiu et al., 2013). Thus, no truly 
new anti-TB lead seem to have successful emerged from target-based 
discovery approach.  
 
Resazurin Microtiter Assay: Simple, Inexpensive Phenotypic Screening 
Method    
 Consequently, phenotypic cell viability screens have become the 
primary high-throughput method for identification of potentially new TB 
leads. The utility of Alamar Blue and other cell viability assays for screening 
of clinical isolates of MTB have been demonstrated: BACTEC TB-460 
system (Collins and Franzblau, 1997), MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium] (Abate et al.,1998; Franzblau et al., 1998, 
Mycobacterium Growth Indicator Tube (Walters and Hanna, 1996), uracil 
uptake (Chung et al., 1995), E-test (Wagner and Mills, 1996), and microplate 
Alamar blue assay Martin et al., 2003; Taneja and Tyagi, 2007),  among 
others. In addition, several studies have clearly shown the reliability of 
Alamar blue cell viability assay for detection of drug resistant MTB 
(Palomino et al., 2002; Bwanga et al., 2009). The resazurin-based assay is a 
simple, inexpensive method with very high diagnostic accuracy, and lends 
itself to easy use in countries or even laboratories with limited resources 
(Chauca et al., 2007).  
 
1.3 Mycobacterium smegmatis as potential surrogate for MDRTB 
     Expectedly, the highly infectious nature of MDRTB is a limiting 
factor in its use in high throughput screening of probable new TB agents. 
Fortunately, the utility of M. smegmatis in screening for compounds active 
against MDRTB was recently demonstrated by Chaturvedi and coworkers 
(Chaturvedi et al., 2007). M. smegmatis does not require specialized 
containment facilities, grows relatively fast, and is a good predictor of 
activity against MDRTB (Chung et al., 1995; Chaturvedi et al., 2007; Li et 
al., 2004).  In addition, M. smegmatis is known to exhibit natural resistance 
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to isoniazid (INH) and rifampicin (Chung et al., 1995; Chaturvedi et al., 
2007; Quan et al., 1997). Therefore, in screening selected household 
chemicals for activity, we have chosen M. smegmatis based on previous 
studies establishing the reliability of M. smegmatis as a selective, non-
pathogenic, fast growing surrogate for clinical isolates of MDRTB. 
 In the current study, we investigate the anti-tubercular activity of 
common household chemicals (boric acid, disodium ethylene diamine 
tetracetic acid - EDTA, benzoyl peroxide, lauric acid), paracetamol and 
nonsteroidal anti-inflammatory analgesic (aspirin, ibuprofen, Aleve) against 
M. smegmatis, as a non-pathogenic, fast growing surrogate for multidrug 
resistant TB.  These are safe, cheap, readily available chemicals with known 
pharmacological profiles, which can be easily and safely deployed as anti-
tubercular agents. The objective then is to investigate their potential 
application for treatment of MDRTB. 
 Selection of household chemicals was partially based on a ligand-
based approach. Since multidrug resistant strains of MTB are resistant to INH 
and RMP, our running hypothesis is that drugs that effectively inhibit the 
Enoyl-[acyl-carrier-protein] reductase (InhA), with a different mechanism of 
action from that of INH’s role on the same enzyme, may circumvent this 
resistance. Indeed, several studies seem to bear out this rationale (Vilchèze et 
al., 2011; Sullivan et al., 2006)). So, an initial virtual screening was done by 
docking selected ligands into the active site of InhA receptor (PDB id= 2nsd; 
resolution of 1.900), to predict drugs likely to bind enzyme target very well. 
Also, as part of our continued search for potent inhibitors of antigen 85 
complex, an acyltransferase enzyme implicated in the synthesis of cord 
factor and final assembly of mycobacterial cell wall, household chemicals 
with functional groups known to either inhibit serine or related proteases 
were chosen (Umesiri et al., 2010). Therefore, selected ligands were also 
docked into antigen 85C receptor (PDB id= 1va5; resolution of 2.020). This 
approach of combining initial ligand-based rationality with phenotypic 
whole-cell screening may help to provide preliminary insight into the 
possible molecular mechanisms of action of select molecules. 
 
Materials and Methods 
Materials  
 M. smegmatis (ATCC 607) was procured from 
American Type Culture Collection Company (ATCC). INH and other drugs 
and chemicals were sourced directly from manufacturers through VWR 
International, and used without further purification. Fresh stock of drugs and 
chemicals were prepared and used fresh for each experiment. For disodium 
ETDA, lauric acid, boric acid, aspirin, ibuprofen, naproxen (Aleve), and 
benzoyl peroxide, original stock of drug was prepared in dimethyl sulfoxide 
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(DMSO) or water at 10 mg/mL. For INH, original stock was prepared in 
DMSO at 1 mg/mL.   
 
Molecular docking 
 Molecular docking was carried out with 1-Click Docking tool 
(Mcule, 2014), a web-based docking application based on Autodock Vina 
configuration (Trott and Olson, 2010). Virtual screening was done by 
docking selected ligands differently into the active site of InhA receptor 
(PDB id= 2nsd; resolution of 1.900) and antigen 85C receptor (PDB id= 
1va5; resolution of 2.020). Since our internal docking experiment shows that 
docking results obtained with either AutoDockVina directly or the 1-Click 
Docking application were almost identical, we have chosen to use the 1-
Click Docking application due to the fact that it is easier, more user-friendly, 
and meets our current needs. Its limitation is that it may not be adequate for 
customized advanced docking studies. 
 
Preparation of 7H10 Agar  
 Preparation of 7H10 Middlebrook Agar medium for M. smegmatis 
growth followed protocols provided by manufacturer, DifcoTM Middlebrook. 
To make a half liter batch, 9.5g 7H10 agar was dissolved in 450 mL ultra-
purified water in a 1 liter bottle, and 2.5 mL glycerol was added to mixture 
pipetted using a P-1000 micropippette. The whole mixture was dissolved in 
microwave for 2 minutes, autoclaved at 121°C for 20 min, and cooled in a 
50°C water bath. Afterwards, 50 mL of Middlebrook OADC (oleic acid 
dextrose catalase) enrichment was poured into the medium aseptically. The 
enrichment was gently swirled into the agar solution to prevent bubble 
formation. Sterile plates were set out and agar was poured halfway up the 
plate, enough to keep the bacteria growing longer. If bubbles appeared, they 
were flamed gently using a Bunsen burner. It is important to keep the top 
surface of the agar flat. After all plates were filled, they were stacked upright 
and left out in room temperature for one day to solidify, and then stored at 
4°C. 
 
Preparation of 7H9 broth 
 Using aseptic methods, and following manufacturer’s instructions, 
Middlebrook 7H9 Broth was prepared. To make a 500 mL batch, 0.94g 7H9 
broth was dissolved in 200 mL ultra-purified water in a 1 liter bottle. Using a 
P-1000 micropipette with a cut tip, 0.4 mL glycerol was added to the 
mixture, heated in the microwave for 2 minutes to ensure complete 
dissolution. The broth was autoclaved at 121°C, and was cooled in a 45°C 
water bath. Next, 40 mL of Middlebrook ADC Enrichment was poured into 
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the medium and stirred. 5mL 7H9 broth was quickly added to sterile tubes 
and then capped, and stored at 4°Cbefore using in bacterial cultures.  
 
Bacterial Culture and CFU Counting 
 Fresh isolates of Mycobacterium smegmattis (ATCC 14468) were 
cultured in Middlebrook 7H11 agar for every experiment. Capped tubes 
containing pre-made sterile 7H9 broth were warmed to room temperature 
before inoculating. Meanwhile, an agar plate containing colonies of M. 
smegmatis was already prepared. A colony of the bacteria was transferred 
aseptically to 7H9 broth, and incubated at 37°C for 3 days.  
 
CFU counting  
 Bacterial cultures were diluted to an optical density of OD595 = 0.01 
(=4.7 x 105 Colony forming units (CFU) per mL). 100 μL of different 
dilutions (10−1, 10−2, 10−3, 10−4, 10−5) were spread (in triplicate) on Petri 
dishes containing 25 mL of OADC supplemented Middlebrook 7H10. The 
cultures were incubated at 37°C for 3 days and the number of colonies was 
counted.  
 
Resazurin microtiter assay (REMA) 
 The resazurin microtiter assay (REMA) plate method was performed 
in 7H9 medium containing Middlebrook broth and 0.5% glycerol and 
supplemented with oleic acid, albumin, dextrose, and catalase (DifcoTM). 
Clear- 96-well plates were inoculated with 100 μL of drug diluted with 90 µl 
of 7H9 medium and 10 µL DMSO (giving essentially 50 µL of drug).  Serial 
twofold dilutions of each drug in 100 µL of 7H9 medium were prepared at 
concentrations of 0.5 to 0.0039 mg/mL for all drugs, and 0.05 to 0.00039 
mg/mL for INH. Growth controls containing no antibiotic and sterility 
controls without inoculation were also included (Figure 2). To the column 
containing the control with no bacteria, 10 μL DMSO and 190 μL 7H9 
medium was added. To the column containing the control with no drug, 10 
μL DMSO, 90 μL 7H9 medium, and 100 μL of bacteria culture were added. 
Finally, 200 μL of sterile deionized water was added to the outer perimeter 
wells to prevent evaporation during incubation of the plate. The lid was 
placed back on the plates and partially sealed with parafilm to allow for air 
circulation. The plates were incubated plate at 37°C for 3-4 days. After 
incubation, the plates were removed and 10 μL of resazurin was added to 
each well that contained bacteria. More water was added to the outer 
perimeter wells when necessary. The plates were reincubated at 37°C for 24- 
48 hours and visually assessed for color development. A change from blue to 
pink indicates reduction of resazurin to resorufin, and therefore an indication 
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of bacterial growth. The MIC was defined as the lowest drug concentration 
that prevented this color change, by direct visual examination. 
 
Results 
Molecular docking 
 The best fit pose with the lowest binding energy from initial 
molecular docking is chosen, and the binding affinity for each ligand with 
antigen 85C and InhA is reported in kcal/mol (Table 2). Interestingly, the 
binding affinity of each ligand is very similar for both InhA and antigen 85C. 
 
Minimum inhibitory concentration (MIC) 
 MIC results from the resazurin-based screening are tabulated in Table 
3; showing that lauric acid and EDTA had the lowest MIC values, at 7.8 
µg/mL, and 3.1 µg/mL respectively. The MIC for INH, the positive control 
is at 6.2 µg/mL. As for acetaminophen and the three over-the-counter 
NSAIAs, aspirin and ibuprofen showed the highest activity against M. 
smegmatis, with MIC of 125 µg/mL (Table 3, and Figure 1). 
Table 3: Binding affinity of ligands with Antigen 85C and InhA 
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Discussion 
 Adopting a ligand-based approach, four over-the-counter analgesics ( 
aspirin, Aleve, acetaminophen, ibuprofen) and four household chemicals 
(benzoyl peroxide, lauric acid, boric acid, and disodium salt of  
Ethylenediaminetetraacetic acid, EDTA) were chosen for antibacterial 
activity against MDRTB using M. smegmatis as a non-pathogenic, fast 
growing surrogate.  Our approach involved selection of common household 
chemicals for anti-tubercular screening based on their ability to successfully 
bind and potentially inhibit InhA (Table 2).  
 Benzoyl peroxide (BP) is a common over-the-counter medication for 
acne vulgaris with broad antibacterial activity. BP has certain characteristics 
that make it potentially an attractive agent to investigate for anti-MDRTB 
activity: the ability to penetrate high-lipid environments typical of the 
mycobacterial cell wall (Decker et al. 989), successful use of 5% 
concentration in treating drug-resistant strains of Propionibacterium acnes 
(Dutil, 2010), and its ability to prevent the selection of erythromycin-
resistant Staphylococcus epidermidis (Eady et al., 1996). Initial molecular 
docking carried out with Mcule’s 1-Click Docking tool showed that benzoyl 
peroxide binds well to the active site of InhA, a target of isoniazid; with a 
binding affinity of -8.3 kcal/mol (Table 2).  
Table 4: MIC values for household chemicals screened 
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 As it turns out, the MIC for benzoyl peroxide using REMA was 
rather high at 250 µg/mL (Table 3 and Figure 1); although its zone of 
inhibition (17 mm) on Kirby-Bauer disk diffusion assay was decent 
compared to INH (29 mm), Table 4 and Figure 2. As a radical initiator, its 
potential application as a fumigation agent against drug-susceptible and 
drug-resistant MTB in hospitals and related facilities may be more important. 
5% vaporized hydrogen peroxide (50,000 µg/mL) has been shown to be 
effective as fumigation agent against clinical isolates of MTB (Kahnert et al., 
2005; Grare et al., 2008). With MIC of 250 µg/mL, benzoyl peroxide 
appears to be a more potent anti-TB fumigation agent than hydrogen 
peroxide. 
 The antimicrobial activity of lauric acid and other medium-chain 
fatty acid have been reported (Kabara et al., 1972; Nakatsuji et al., 2009; 
Kanetsuna, 1985). For example, lauric acid was shown to inhibit 
Propionibacterium acnes at a MIC of 3.9 µg/mL. But here, we effectively 
demonstrate the potential of lauric acid to inhibit drug-resistant TB using M. 
smegmatis as a surrogate, based on resazurin-based microtiter assay plate. At 
a MIC of 7.8 µg/mL against M. smegmatis, lauric acid appears potent enough 
to be considered a cheap and practical treatment option for MDRTB, 
especially in combination with other TB drugs. As a naturally occurring 
chemical which is present in coconut oil, breast milk, among others, lauric 
acid is nontoxic, safe, inexpensive, and has a long shelf-life.  
 Even though EDTA has been known to exhibit general antibacterial 
activity, especially against metalloenzymes and proteases at 32 μg/ml 
(Upadhye et al., 2009; Aoki et al., 2010), this study demonstrates, for the 
first time as far as we know, its potential utility in treating MDRTB by 
utilizing the innate resistance M. smegmatis against INH. EDTA showed 
significant antitubercular activity against M. smegmatis with MIC of 31 
µg/mL. 
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Figure 7: Minimum inhibitory concentration values of a) common household chemicals 
(EDTA, lauric acid, benzoyl peroxide, boric acid), and b) acetaminophen and NSAIDs; with 
INH as positive control. 
 
 The structural resemblance of EDTA to disulfiram, an alcoholism 
drug which has shown potent anti-tubercular activity against drug-resistant 
TB at MIC of 1.56 µg/mL is not lost on us (Horita et al., 2012). In that study, 
disulfiram exhibited activity against M. smegmatis at MIC of 25 µg/mL, 
which is very comparable to the results we obtained with EDTA. Further in 
vitro and in vivo studies involving EDTA against clinical isolates of MDRTB 
is therefore warranted.  
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Table 5: Zone of inhibition from Kirby-Bauer disk assay 
 
 
 Boric acid has long been used for medical applications due to its 
antiseptic, phagocyticidal, antibacterial properties, especially as a topical 
application for burns or acne, typically at MIC of 2% (Novak & Taylor, 
1951). Boric acid showed some activity against M. smegmatis at MIC of 500 
µg/mL which is more potent than a 2% concentration (20,000 µg/mL) of 
boric acid used for other indications. Still, 500 µg/mL MIC appears to be too 
large compared to NIH. Therefore, boronic acid derivatives of larger 
molecules might be better alternatives than boric acid itself, as shown by our 
current synthetic efforts with boronic-aurone derivatives (unpublished data).   
 
Figure 8: Kirby-Bauer disk showing antimycobacterial activity of benzoyl peroxide (4) 
compared to INH (5). 
 
 Some of the chemicals tested (EDTA, boric acid, aspirin and 
acetaminophen) showed little or no inhibition using Kirby-Bauer disk assay 
(Table 4) but exhibited some mycobacterial activity using resazurin 
microtiter assay. This may be due to the fact that precipitation was observed 
for each of those four chemicals on the disk assay, which may have affected 
rate of diffusion and therefore inhibition. A similar effect was also observed 
by Juárez-Hernándeza et al. (2012) when screening synthetics using both 
Kirby-Bauer diffusion and MIC methods. The result also suggests that 
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REMA may be a more sensitive susceptibility test, especially with regard to 
M. smegmatis (Jorgensen & Ferraro, 1998). 
 
Conclusion 
 Using M. smegmatis as a potential surrogate for MDRTB, we have 
screened a range of household chemicals, including EDTA, lauric acid, 
benzoic acid, and common over-the-counter analgesics for anti-tuberculosis 
activity through resazurin-based microtiter assay. Of the household 
chemicals examined, EDTA and lauric acid showed the highest activity with 
MIC of 31 µg/mL and 7.8 µg/mL respectively. Of the four analgesics tested, 
ibuprofen and aspirin showed the highest activity against M. smegmatis, with 
MIC of 125 µg/mL. Naproxen, and acetaminophen showed the same MIC at 
250 µg/mL. Results obtained suggest that the use of these chemicals in 
combinatorial therapy against drug-susceptible and MDRTB needs to be 
further investigated. In fact, a recent study showed that the use of 20 mg/mL 
of ibuprofen (oral dose of 80 mg/kg) in adjuvant tuberculosis treatment in 
murine model of active TB was effective (Vilaplana et al., 2013). Taken 
together, the current study is important because it demonstrates, for the first 
time, the potential of EDTA, lauric acid and common analgesics in the 
treatment of drug-resistant tuberculosis, using M. smegmatis as surrogate for 
MDRTB. Finally, there is a need to carry out further testing using clinical 
isolates of MDRTB; which constitutes future direction of the above study. 
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